The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Open accessAbstract
BACKGROUND: Previous studies have reported additional cancers associated with BRCA mutations; however, the type, magnitude of risk, and sex differences remain to be clarified. The purpose of this study was to evaluate the incidence of cancers other than breast and ovarian cancer in known mutation carriers. METHODS: An institutional review board–approved study identified 1072 patients who had genetic counseling at the authors' institution and tested positive for a deleterious BRCA mutation. The expected number of cancer cases was calculated from the number of individuals in the study sample multiplied by the cancer incidence rates for the general population. The expected and observed numbers of cases were calculated in 5‐year intervals to accommodate different age‐related incidence rates. Standardized incidence ratios (SIRs) for each cancer type were calculated. RESULTS: Among the 1072 mutation carriers, 1177 cancers of 30 different cancer types were identified. Individuals with a BRCA1 mutation did not have a significant increase in cancers other than breast and ovarian cancer; however, a trend in melanoma was observed. Individuals with a BRCA2 mutation had significantly higher numbers of observed cases versus expected cases for pancreatic cancer in both men and women (SIR, 21.7; 95% confidence interval [CI], 13.1‐34.0; P < .001) and for prostate cancer in men (SIR, 4.9; 95% CI, 2.0‐10.1; P = .002). CONCLUSIONS: The results of this study uphold the current recommendations for hereditary breast and ovarian cancer screening of cancers other than breast and ovarian cancer by the National Comprehensive Cancer Network. Larger cohorts and collaborations are needed to further verify these findings. Cancer 2015;121:269–75. © 2014 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850 · cited 2×
“BRCA1 mutations have also been linked to increases in cervical, esophageal, liver, stomach, and uterine cancers; however, the increased risks have been inconsistent and have ranged from 1- to 4-fold.(9-12) Known environmental risk factors associated with these cancers have not typically been reported in these studies.”
BackgroundBreast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Saam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationCancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · cited 1×
“Investigational protocols into pancreatic screening include endoscopic ultrasound and/or magnetic resonance imaging cholangiopancreatography rather than computed tomography scans; however, there is inconsistency in follow-up intervals, and when fine-needle aspirations are needed continues to be debated.(25-27) The hig…”
BackgroundCancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648 · cited 1×
“Investigational protocols into pancreatic screening include endoscopic ultrasound and/or magnetic resonance imaging cholangiopancreatography rather than computed tomography scans; however, there is inconsistency in follow-up intervals, and when fine-needle aspirations are needed continues to be debated.(25-27) The hig…”
BackgroundGenetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Self-citationEpidemiology and risk factors for pancreatic cancer
Lowenfels, A. B., & Maisonneuve, P. (2006) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.10.001 · Cited by 635
Moscicki, A.-B., Shiboski, S., Broering, J., Powell, K., Clayton, L., Jay, N., Darragh, T. M., Brescia, R., Kanowitz, S., Miller, S. B., et al. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70445-7 · Cited by 564
Breast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm203 · Cited by 430
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., Weber, B. L., Eisen, A., Peterson, L. E., Schildkraut, J. M., Isaacs, C., Peshkin, B. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6772 · Cited by 317
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
de Acosta, J., & Markham, C. R. (2009) · Cambridge University Press eBooks · Cited by 266
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.483 · Cited by 252
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
the Hereditary Breast Cancer Study Group, Phelan, C. M., Iqbal, J., Lynch, H. T., Lubiński, J., Gronwald, J., Møller, P., Ghadirian, P., Foulkes, W. D., Armel, S. R., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.741 · Cited by 139
Bermejo, J. L., & Hemminki, K. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh474 · Cited by 77
Screening for Pancreatic Cancer in High-Risk Individuals: A Call for Endoscopic Ultrasound
Larghi, A., Verna, E. C., Lecca, P. G., & Costamagna, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1966 · Cited by 47
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis
Cai, J., Chen, H., Lu, M., Zhang, Y., Lu, B., You, L., Zhang, T., Dai, M., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.027 · Cited by 470
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.10987 · Cited by 467
Metadata
- Authors
- Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2014-09-15
- Volume
- 121
- Issue
- 2
- Pages
- 269-275
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1929113708
- Cited by
- 511
- References
- 28
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.